Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Roth

Showing results (321-330 of 396) with videos related to

Pageof 40
Sort By:
Journal of Sleep Research|August 25, 2025
Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of NarcolepsyLuis E Ortiz, Anne Marie Morse, Michael J Thorpy, et al.
Clinical Therapeutics|April 2, 2013
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adultsDavid J Greenblatt, Jerold S Harmatz, Thomas Roth, et al.
CNS Drugs|April 5, 2022
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialThomas Roth, Yves Dauvilliers, Michael J Thorpy, et al.
Nature and Science of Sleep|July 27, 2018
Hyperarousal and sleep reactivity in insomnia: current insightsDavid A Kalmbach, Andrea S Cuamatzi-Castelan, Christine V Tonnu, et al.
Sleep Advances : a Journal of the Sleep Research Society|May 16, 2023
Validation of Somno-Art Software, a novel approach of sleep staging, compared with polysomnography in disturbed sleep profilesLaurie Thiesse, Luc Staner, Patrice Bourgin, et al.
Journal of Child and Adolescent Psychopharmacology|April 12, 2011
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorderScott H Kollins, Frank A López, Bradley D Vince, et al.
The Lancet. Neurology|January 22, 2022
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, David Mayleben, Ingo Fietze, et al.
Sleep|February 26, 2009
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndromeClete A Kushida, Arthur S Walters, Philip Becker, et al.
Sleep Medicine|May 16, 2022
Performance of Somno-Art Software compared to polysomnography interscorer variability: A multi-center studyLaurie Thiesse, Luc Staner, Gil Fuchs, et al.
Sleep Medicine|February 27, 2022
Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorderThomas Roth, Russell Rosenberg, Charles M Morin, et al.
Pageof 40

Showing results (321-330 of 396) with videos related to

Sort By:
Pageof 40
Journal of Sleep Research|August 25, 2025
Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of NarcolepsyLuis E Ortiz, Anne Marie Morse, Michael J Thorpy, et al.
Clinical Therapeutics|April 2, 2013
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adultsDavid J Greenblatt, Jerold S Harmatz, Thomas Roth, et al.
CNS Drugs|April 5, 2022
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialThomas Roth, Yves Dauvilliers, Michael J Thorpy, et al.
Nature and Science of Sleep|July 27, 2018
Hyperarousal and sleep reactivity in insomnia: current insightsDavid A Kalmbach, Andrea S Cuamatzi-Castelan, Christine V Tonnu, et al.
Sleep Advances : a Journal of the Sleep Research Society|May 16, 2023
Validation of Somno-Art Software, a novel approach of sleep staging, compared with polysomnography in disturbed sleep profilesLaurie Thiesse, Luc Staner, Patrice Bourgin, et al.
Journal of Child and Adolescent Psychopharmacology|April 12, 2011
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorderScott H Kollins, Frank A López, Bradley D Vince, et al.
The Lancet. Neurology|January 22, 2022
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, David Mayleben, Ingo Fietze, et al.
Sleep|February 26, 2009
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndromeClete A Kushida, Arthur S Walters, Philip Becker, et al.
Sleep Medicine|May 16, 2022
Performance of Somno-Art Software compared to polysomnography interscorer variability: A multi-center studyLaurie Thiesse, Luc Staner, Gil Fuchs, et al.
Sleep Medicine|February 27, 2022
Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorderThomas Roth, Russell Rosenberg, Charles M Morin, et al.
Pageof 40